Figure 4
SiRNAs against HER2 could abrogate the EMT phenotype and cell invasiveness in cisplatin-resistant gastric cancer cells.
(A) Validation of silencing efficiency of HER2. Cells were transiently transfected with 50 nM HER2-specific siRNAs #1-#3 or a control siRNA for 48 h. (B) Knock-down of HER2 abrogated EMT morphology. Cells were transiently transfected with 50 nM specific siRNAs targeting HER2 for 48 h, Representative images of cellular morphology were shown. (C) Knock-down of HER2 abolished EMT phenotype. Cells were treated as in Fig. 4B. FITC-phalloidin staining of F-actin were performed and representative images were shown. (D) Effects of HER2 knock-down on the levels of ZO1 and Snail. (E) Effects of HER2 knock-down on cell migration. Representative images of transwell cell migration assay were shown. (F) Summary of Fig. 4E. Values represented the mean ± SD from three independent experiments with triplicate samples. *P < 0.01.
